AstraZeneca PLC (AZN)vsInfuSystems Holdings Inc (INFU)
AZN
AstraZeneca PLC
$185.48
-0.59%
HEALTHCARE · Cap: $293.73B
INFU
InfuSystems Holdings Inc
$14.79
-1.92%
HEALTHCARE · Cap: $261.91M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 43423% more annual revenue ($62.38B vs $143.34M). AZN leads profitability with a 17.7% profit margin vs 6.0%. AZN appears more attractively valued with a PEG of 1.35. AZN earns a higher WallStSmart Score of 68/100 (B-).
AZN
Strong Buy68
out of 100
Grade: B-
INFU
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.3%
Fair Value
$197.94
Current Price
$185.48
$12.46 discount
Margin of Safety
+27.7%
Fair Value
$10.53
Current Price
$14.79
$4.26 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 29.6%
Earnings expanding 23.5% YoY
Generating 4.0B in free cash flow
Earnings expanding 25.0% YoY
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
2.6% revenue growth
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 29.6%. PEG of 1.35 suggests the stock is reasonably priced for its growth.
Bull Case : INFU
The strongest argument for INFU centers on EPS Growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : INFU
The primary concerns for INFU are PEG Ratio, P/E Ratio, Revenue Growth.
Key Dynamics to Monitor
AZN profiles as a mature stock while INFU is a value play — different risk/reward profiles.
INFU carries more volatility with a beta of 1.38 — expect wider price swings.
AZN is growing revenue faster at 6.7% — sustainability is the question.
AZN generates stronger free cash flow (4.0B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (68/100 vs 56/100), backed by strong 17.7% margins. INFU offers better value entry with a 27.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
InfuSystems Holdings Inc
HEALTHCARE · MEDICAL DEVICES · USA
InfuSystem Holdings, Inc., provides infusion pumps and related products and services in the United States and Canada. The company is headquartered in Rochester Hills, Michigan.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?